Lakefront Biotherapeutics NV current report, Q4 FY2023

SEC Filing Summary: Form 6-K

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of October 2023. The filing, dated November 2, 2023, serves to incorporate by reference a press release issued on October 30, 2023 (Exhibit 99.1). The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Form 20-F.

Financial Metrics

The filing text provided does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a conduit for the attached press release.

Material Changes

The filing text does not provide details on material changes versus prior periods. The content is limited to the administrative incorporation of the October 30, 2023, press release.

Guidance, Outlook, and Risks

Specific guidance, outlook, management commentary, risks, or contingencies are not detailed in the body of this Form 6-K. The document notes that quotes from Dr. Paul Stoffels, Thad Huston, and Francesco Balestrieri are included in Exhibit 99.1 but are not reproduced in the filing text provided. Investors must refer to the attached press release for these details.

Key Facts for Investor Verification

  • Verify the actual registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
  • Review Exhibit 99.1 (the press release dated October 30, 2023) for the substantive news, as this Form 6-K contains no operational or financial data.
  • Confirm the specific content of the press release regarding the quotes from Dr. Paul Stoffels, Thad Huston, and Francesco Balestrieri.
  • Note that this filing incorporates information into multiple Registration Statements on Form S-8.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.